Mr. Speaker, I thank the gentleman for yielding me time. This an important discussion. Maybe it would be reasonable, Mr. Speaker, to start out trying to explain what is biotechnology? Gregor Mendel discovered dominant and recessive traits…
Mr. Speaker, I thank the gentleman for yielding me time.
This an important discussion. Maybe it would be reasonable, Mr. Speaker, to start out trying to explain what is biotechnology?
Gregor Mendel discovered dominant and recessive traits in plants in the mid 19th century. He started taking two quality plants and crossing them to see if you could come out with an improved variety. So we have had cross-breeding, we have had hybrid breeding ever since. Now we have finished gene cataloguing of an agricultural plant called the Arabidopsis, a mustard plant.
But with 25,000 genes, you just took your chances when mixing two plants together. Sometimes the product turned out poisonous or allergenic. Sometimes it was very undesirable for a raft of other reasons.
Now we have the scientific technology to pick out one single gene and decide what characteristics are going to evolve from that gene, and instead of taking your chances by mixing 25,000 or 30,000 genes of two plants, you pick out one gene because you want a certain characteristic. You put it into that other plant and predetermine what is going to happen as a result.
Now, there is a lot of scare of what might happen generations from now. In the discussion of this resolution, it seems to me that we should not be debating whether this is a trade issue. This is now going to be in the hands of the WTO to decide whether or not it is unfair. But everybody, Mr. Speaker, needs to understand, other countries are trying to keep our products out of their country for one reason or another, restricting imports for bio sanitary reasons or anything else they can come up with. And in this case, it appears that they are trying to keep our agricultural products, that we produce more efficiently, out of Europe and Japan and some of these other countries, simply because they do not want it to disrupt the problems of their farmers and they want to protect their markets. We are going to let the WTO decide if it is restraint of trade. But as we evolve into greater assurance that we are going to have safety, both to human health, to animals, and to the environment, we need to move ahead with this technology.
Look, the possibilities in developing countries are so tremendous. That is why our whip mentioned that the day after tomorrow I am holding a hearing on biotechnology. The Speaker is going to lead off the testimony in that hearing on the potential and safety of biotechnology. We are going to have Rita Caldwell from NSF come to tell us about the implementation of what we put in my NSF bill in terms of working with African scientists, developing products that are going to help their particular country. And if we get into Africa, eventually, science and biotechnology are going to prevail. We are going to have Mr. Natsios, the administrator of AID, say how important it is that we do not restrict this technology for developing countries.
Vote for this resolution and vote to let science, not emotion, rule the future of agricultural biotechnology.
On May 12th, the Speaker of the House and members of Congress joined with the Bush Administration to challenge the European Union's import ban on genetically modified (GM) crops. WTO rules, while allowing countries to reject imports on the basis of health and environmental concerns, require that any such policy be supported by scientific evidence.
However, the EU has refused to process new applications for trade of transgenic food crops since 1998 without even attempting to demonstrate any compelling scientific reasons. It is estimated that over $300 million annually in U.S. corn exports alone are being lost. Even EU Enviroment Commissioner Margot Wallstrom has admitted that, ``We have already waited too long to act. The moratorium is illegal and not justified.''
While the EU stance on GM crops is an unfair economic burden on American farmers, it is also an unjust burden on the world's poorest continent. With approximately 180 million undernourished people, Africa stands to benefit tremendously from GM crops.
The EU is exploiting Africa's dependence on the EU market to stall acceptance of GM crops. For example, with its population literally starving last year, Zambia rejected 23,000 metric tons of U.S. food aid because Europe might reject future Zambian corn exports. EU pressure is even impeding research on new transgenic crop varieties important to bringing Africa closer to sustainability.
The Speaker of the House, USAID Administrator, and leading scientists will testify at my Research Subcommittee hearing this Thursday. We will examine barriers to plant biotechnology in Africa and new government programs supporting partnerships with African scientists in Africa.
The U.S. challenge moves us one step closer to removing unfair barriers that hurt American farmers and deny the people of Africa a tool for combating hunger. Please support H. Res. 252.
Mr. Speaker, I include for the Record a summary of a report we wrote on biotechnology in the Committee on Science called ``Seeds of Opportunity.'' The total report is available at: www.house.gov/nicksmith/opportunity.pdf.
The report referred to is as follows:
summary
The Subcommittee on Basic Research of the Committee on Science held a series of three hearings entitled, ``Plant Genome Research: From the Lab to the Field to the Market: Parts I-III,'' to examine plant genomics, its application to commercially important crop plants, and the benefits, safety, and oversight of plant varieties produced using biotechnology. The testimony and other information presented at these hearings and information gathered at various briefings provides the basis for the findings and recommendations in this report.
Almost without exception, the crop plants in use today have been genetically modified. The development of new plant varieties through selective breeding has been improving agriculture and food production for thousands of years. In the 19th century, the basic principles of heredity were discovered by Gregor Mendel, whose studies on inheritance in garden peas laid the foundation for the modern science of genetics. Subsequent investigations advanced our understanding of the location, composition, and function of genes, and a critical breakthrough revolutionized the field in 1953, when James Watson and Francis Crick described the double helix structure of deoxyribonucleic acid (DNA), the substance of heredity. This ground breaking research set the stage for deciphering the genetic code and led to the rapid advances in practical application of genetics in medicine, animal science, and agriculture.
The development of the science of genetics in the 20th century was a tremendously important factor in the plant breeding programs that have produced the remarkable diversity of fruits, vegetables, and grains that we enjoy today and that provide food security for the poor nations of the world. Traditional cross-breeding has been very useful in improving crop plants, but it is a time consuming process that results in the uncontrolled recombination of tens of thousands of genes, commonly producing unwanted traits that must be eliminated through successive rounds of backcrossing. Improving crops through traditional methods also is subject to severe limitations because of the constraints imposed by sexual compatibility, which limit the diversity of useful genetic material.
With the arrival of biotechnology, plant breeders are now able to develop novel varieties of plants with a level of precision and range unheard of just two decades ago. Using this technology, breeders can introduce selected, useful genes into a plant to express a specific, desirable trait in a significantly more controlled process than afforded by traditional breeding methods.
U.S. farmers have been quick to adopt plants modified using new biotechnology, including commercial crops that resist biologically insect and viral pests and tolerate broad-spectrum herbicides used to control weeds. As our knowledge of plant genetics expands, new varieties of plants with improved nutrition, taste, or other characteristics desired by consumers will become available. The federally-funded plant genome program provides much of the essential basic research on plant genetics required to develop new varieties of commercially important crops through advanced breeding programs.
For over two decades, the application of biotechnology has been assessed for safety. Oversight of agricultural biotechnology includes both regulatory and nonregulatory mechanisms that have been developed over the last five decades for all crop plants and conventional agricultural systems. Federal regulation of agricultural biotechnology is guided by the 1986 Coordinated Framework for Regulation of Biotechnology, which laid out the responsibilities for the different regulatory agencies, and the 1992 Statement on Scope, which established the principle that regulation should focus on the characteristics of the organism, not the method used to produce it. Three federal agencies are responsible for regulating agricultural biotechnology under existing statutes: the U.S. Department of Agriculture (USDA), which is responsible for ensuring that new varieties are safe to grow; the Environmental Protection Agency (EPA), which is responsible for ensuring that new pest-resistant varieties are safe to grow and consume; and the Food and Drug Administration (FDA), which is responsible for ensuring that new varieties are safe to consume.
Although biotechnology has had an uninterrupted record of safe use, political activists in Europe have waged well-funded campaigns to persuade the public that the products of high-tech agriculture may be harmful to human health and the environment. As a result of these efforts, public confidence in the safety of agricultural biotechnology has been seriously undermined in Europe. Many European countries have established new rules and procedures specifically designed to address ``genetically modified organisms,'' and these have
had a detrimental impact on international trade in agricultural products.
The controversy over agricultural biotechnology now has spread to the United States, the world's largest grower of plants and consumer of foods produced using this technology. At the core of the debate is food safety, particularly the possibility that unexpected genetic effects could introduce allergens or toxins into the food supply. The use of antibiotic resistance markers also has been criticized as dangerous to human health. As a result, there have been calls for both increased testing and labeling requirements for foods created using biotechnology.
Environmental concerns also have been raised. It has been suggested, for example, that widespread use of plants engineered with built-in protection against insect and viral pests could accelerate the development of pesticide-resistant insects or could have a negative impact on populations of beneficial insects, such as the Monarch butterfly. It also has been argued that the use of herbicide-tolerant plants could increase herbicide use and that ``superweeds'' could be developed through cross-pollination between these plants and nearby weedy relatives.
Extensive scientific evaluation worldwide has produced no evidence to support these claims. Far from causing environmental and health problems, agricultural biotechnology has tremendous potential to reduce the environmental impact of farming, provide better nutrition, and help feed a rapidly growing world population. Crops designed to resist pests and to tolerate herbicides and environmental stresses, such as freezing temperatures, drought, and high salinity, will make agricultural more efficient and sustainable by reducing synthetic chemical inputs and promoting no-tillage agricultural practices. Stress-tolerant crops also will reduce pressure on irreplaceable natural resources like rainforests by opening up presently nonarable lands to agriculture. Other plants are being developed that will produce renewable industrial products, such as lubricating oils and biodegradable plastics, and perform bioremediation of contaminated soils.
Biotechnology will be a key element in the fight against malnutrition worldwide. Deficiencies of vitamin A and iron, for example, are very serious health issues in many regions of the developing world, causing childhood blindness and maternal anemia in millions of people who rely on rice as a dietary staple. Biotechnology has been used to produce a new strain of rice--Golden Rice--that contains both vitamin A (by providing its precursor, beta-carotene) and iron. The Subcommittee heard about other research aimed at improving the nutrition of a wide variety of food staples, such as cassava, corn, rice, and other cereal grains, that can be a significant help in the fight for food security in many developing countries.
The merging of medical and agricultural biotechnology has opened up new ways to develop plant varieties with characteristics to enhance health. Advanced understanding of how natural plant substances, known as phytochemicals, confer protection against cancer and other diseases is being used to enhance the level of these substances in the food supply. Work is underway that will deliver medicines and edible vaccines through common foods that could be used to immunize individuals against a wide variety of enteric and other infectious diseases. These developments will have far-reaching implications for improving human health worldwide, potentially saving millions of lives in the poorest areas of the world by providing a simpler medicine production and distribution system.
Set against these benefits, however, is the idea that transferring a gene from one organism to an unrelated organism using recombinant DNA techniques inherently entails greater risks than traditional cross breeding. The weight of the scientific evidence leads to the conclusion that there is nothing to substantiate scientifically the view that the products of agricultural biotechnology are inherently different or more risky than similar products of conventional breeding.
The overwhelming view of the scientific community--including the National Academy of Sciences, the National Research Council, many professional scientific societies, the Organization for Economic Cooperation and Development, the World Health Organization, and the research scientists who appeared before the subcommittee--is that risk assessment should focus on the characteristics of the plant and the environment into which it is to be introduced, not on the method of genetic manipulation and the source of the genetic material transferred. These risk factors apply equally to traditionally-bred plants.
Years of research and experience demonstrate that plant varieties produced using biotechnology, and the foods derived from them, are just as safe as similar varieties produced using classical plant breeding, and they may even be safer. Because more is known about the changes being made and because common crop varieties with which we have a broad range of experience are being modified, plants breeders can answer questions about safety that cannot be answered for the products of classical breeding techniques.
FDA has adopted a risk-based regulatory approach consistent with these principles and with the long history of safe use of genetically- modified plants and the foods derived from them. Its policies on voluntary consultation and labeling are consistent with the scientific consensus and provide essential public health protection.
Unlike FDA regulations on food, USDA has instituted plant pest regulations, and EPA proposes to institute new plant pesticide regulations, that target selectively plants produced using biotechnology and apply substantive regulatory requirements to early stages of plant research and development. These regulations add greatly to the cost of developing new biotech plant varieties, harming both an emerging industry and the largely publicly-funded research base upon which it depends. Regulations and regulatory proposals that selectively capture the products of biotechnology should be modified to reflect the scientific consensus that the source of the gene and the methods used to transfer it are poor indicators of risk.
In the international area, the United States should work to ensure that access to existing markets for agricultural products are maintained. The United States should not accept any international agreements that endorse the precautionary principle--which asserts that governments may make political decisions to restrict a product even in the absence of scientific evidence that a risk exists--and that depart from the principle of substantial equivalence adopted by a number of international bodies.
Finally, the administration, industry, and scientific community have a responsibility to educate the public and improve the availability of information on the long record of safe use of agricultural biotechnology products. This is critically important to building consumer confidence and ensuring that sound science is used to make regulatory decisions.